

GR H-score correlates with tumor and immune infiltrate
Region
Cell type
R²
p-value
tumor FOXP3+ 0.58 0.0072
stroma FOXP3+ 0.38 0.051
tumor CD3+ 0.50 0.01
stroma CD3+ 0.46 0.0146
tumor PD1+ 0.33 0.0488
stroma PD1+ 0.30 0.0662
tumor CD57+ 0.52 0.0038
stroma CD57+ 0.54 0.0063
TNBC Melanoma
tumor FOXP3+
stroma FOXP3+
tumor CD3+
stroma CD3+
tumor PD1+
stroma PD1+
tumor CD57+
stroma CD57+
cell counts per unit area
GR H-score
0
100
200
300
2
4
6
8
400
1.0
1.5
2.0
0.5
0.0

FIG. 1



GR expression correlates with PD-L1 expression
R = 0.25, P<2.2e-16
GR expression
7.5
5.0
2.5
0.0
-5
0
5
PD-L1 expression

FIG. 2



GR correlations with suppressed T-cell infiltrate in melanoma
p = 7.6e-08
p = 9.5e-11
GR expression
7.5
5.0
2.5
0.0
0
0.5
1.0
1.5
CD8+ T-cells
0
0.1
0.2
0.3
Regulatory T-cells (Tregs)

FIG. 3A



GR correlations with suppressed T-cell infiltrate in melanoma
p = 5.9e-16
p = 1.4e-05
GR expression
7.5
5.0
2.5
0.0
0
1
2
TH1 cells
TH2 cells

FIG. 3B



Relacorilant restores T-cell activation in the presence of physiological cortisol
% Stimulated control
CD8+/CD137+
150
100
50
0
PHA
αCD3
Unstim
DMSO
Cortisol
CORT125134
Cortisol+CORT125134
% Stimulated control
TNFα
150
100
50
0
PHA
αCD3
Unstim
DMSO
Cortisol
CORT125134
Cortisol+CORT125134
Mean +/- SE

FIG. 4



CD3+ cell surface receptors suppressed by cortisol and rescued by relacorilant
PHA alone vs PHA+cortisol
PHA+ cortisol vs PHA+cortisol+relacorilant
Fold change
64
16
4
1
0.25
0.0625
0.015625
Rescue by relacorilant
Suppression by cortisol
CD8+/CD137+
CD4+/CD137+
CD8+/LAG3+
CD4+/LAG3+
CD4+/CTLA-4+
CD8+/CD27+/CD45RA-
CD4+/Tregs
CD4+/CD27+/CD45RA-
CD4+/PD-1+
CD4+/TIGIT+
CD8+/TIGIT+
Mean +/- SE

FIG. 5



Cytokines/chemokines are suppressed by cortisol and rescued by relacorilant
PHA alone vs PHA+cortisol
PHA+ cortisol vs PHA+cortisol+relacorilant
Fold change
64
16
4
1
0.25
0.0625
0.015625
Rescue by relacorilant
Suppression by cortisol
IFN-γ
IL-12p70
TNF-α
IL-1β
IL-1α
IL-12/IL-23p40
TNF-β
GM-CSF
MIP-1α
IL-6
IL-5
IL-2
MDC
IL-8 (HA)
MIP-1β
IL-7
IL-4
IL-10
IL-13
TARC
IL-15
IL-17A
VEGF
MCP-4
Eotaxin
MCP-1
Eotaxin-3
IL-16
IP-10
Mean +/- SE

FIG. 6A



Cytokines/chemokines are suppressed by cortisol and rescued by relacorilant
αCD3 vs αCD3+cortisol
αCD3+cortisol vs
αCD3+cortisol+relacorilant
Rescue by relacorilant
Suppression by cortisol
Fold change
64
16
4
1
0.25
0.0625
0.015625
IL-8
IL-5
IL-7
IL-13
IL-1β
TNF-α
IL-1α
MIP-1α
IL-8(HA)
GM-CSF
MDC
TNF-β
IL-4
IFN-γ
Eotaxin-3
MCP-1
IL-6
MIP-1β
VEGF
MCP-4
IL-17A
IL-2
IL-16
TARC
IL-15
Eotaxin
IL-10
IP-10
Mean +/- SE

FIG. 6B

Relacorilant promotes αPD1 response in EG7 model




FIG. 7



Detailed comparison of αPD1 vs αPD1+relacorilant
αPD1 alone
Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30
Day post randomization
αPD1 + relacorilant
Tumor volume (mm3)
3000
2000
1000
0
0 10 20 30
Day post randomization
αPD1
αPD1 + relacorilant
% mice with tumor control
100
50
0
0 10 20 30
Day
***
***p=0.002

FIG. 8



Serum IL-10 EG7
serum IL-10
30
20
10
0
pg/ml
Unpaired non-parametric
T-test 0.0015
Group 1
Group 3

FIG. 9



IL8 (CXCL8), IDO1, and EP4 (PTGER4) are suppressed in Phl/II solid tumor study of Relacorilant+ nab-paclitaxel
Baseline vs Day 15
P-value
cxcl8
ptger4
ido1
ptgs2
FDR-Adjusted p-value <0.01
Log2-fold change

FIG. 10

Biomarker summary in patient with CR




FIG. 11

Summary of 'remarkable' responders

Subject ID	Cancer Group	Specific Cancer Type	Best Response	Duration of benefit (weeks)	Failed prior taxane?
014-3009	Other	Vulvar	PR	109	Yes
014-3019	Other	Acinar pancreatic	PR	32	Yes
014-3020	Other	Cholangiocarcinoma	PR	59	No
014-6013	Ovarian	Primary peritoneal	PR	70	No - Adjuvant
038-4004	Ovarian	HGS	CR	23	No - Adjuvant
038-4002	Ovarian	LGS	SD	39	No - Adjuvant
038-6009	Ovarian	LGS	SD	38	Yes
014-3004	PDAC	PDAC	PR	50	Yes
014-3014	PDAC	PDAC	PR	54	No
038-6005	PDAC	PDAC	SD	37	Yes
038-4003	PDAC	PDAC	SD	33	Yes

FIG. 12



Summary of 'remarkable' responders from Phl solid tumor study
Neutrophil/ lymphocyte ratio
Ovarian
Other
Pancreatic
C1D1 C1D8 C1D15
Treg as % of CD4+
C1D-1
C1D8
CD3+ as % of CD45+ mononuclear cells
C1D-1
C1D8
ptgs2 counts
Baseline
C1D15
C7D1
EOT
Visit
IFNγ pg/ml
C1D1
C1D15
IL-10 pg/ml
C1D1
C1D15

FIG. 13



Body weight (grams)
25
20
15
Vehicle
αPD1
relacorilant
αPD1+relacorilant
Tumor volume (mm3)
1000
800
600
400
200
0
Vehicle
αPD1
relacorilant
αPD1+relacorilant

FIG. 14



Unpaired non-parametric p=0.0065
Ova Tetramer+ (% of CD8+ Cells)
2.0
1.5
1.0
0.5
0.0
Vehicle
αPD1
relacorilant
αPD1+relacorilant
Unpaired non-parametric p=0.0122
Ova Tetramer+ (% of CD8+)
8
6
4
2
0
Vehicle
αPD1
relacorilant
αPD1+relacorilant

FIG. 15



PD1+ (% of CD8+)
PD1+ (% of CD8+)
Vehicle
αPD1
relacorilant
αPD1+relacorilant
CD3+CD8+ (% of CD45.1+)
CD3+CD8+ (% of CD45.1+)
Vehicle
αPD1
relacorilant
αPD1+relacorilant
CD69+ (% of CD8+)
CD69+ (% of CD8+)
Vehicle
αPD1
relacorilant
αPD1+relacorilant
* P ≤ 0.05
** P ≤ 0.01
**** P ≤ 0.0001

FIG. 16



TNFα, serum (pg/ml)
5
4
3
2
1
0
Vehicle
αPD1
relacorilant
αPD1+relacorilant
IL6, serum pg/ml
100
80
60
40
20
0
Vehicle
αPD1
relacorilant
αPD1+relacorilant

FIG. 17